Emadoddın TOHIDI, Abolfazl GHANIEI, Hamıd FARZIN, Alıreza HAGHPARAST

Humoral immunity provided by a novel infectious bronchitis vaccine supplemented by bacterium-like particles BLPs

Infectious bronchitis IB is a notable disease of poultry flocks that results in economic loss. As a consequence of the presence of various IB virus IBV serotypes, control strategies, such as vaccination, should be replaced by provide broad protective immunity against the disease to date. Gram-positive enhancer matrix particles, or so-called bacterium like particles BLPs , obtained from the bacterium Lactococcus lactis L. lactis , have demonstrated an adjuvancy effect by providing demanding mucosal and humoral immune responses, as well as a protective cellular immunity whenever delivered admixed with a vaccine via intranasal or intraocular administration. In this study, for the first time, attempts were made to investigate the impact of an IBV vaccine supplemented by various doses of BLPs on induced levels of humoral immunity against IB. For this purpose, increasing doses of derived BLPs 0, 0.15, 0.3, and 0.6 mg dry weight per bird were admixed with IBV live attenuated H120 serotype vaccine, and were delivered via ocular administration to 4 equal groups of 10 specific pathogen-free SPF chickens in 4 groups: control, BLP1, BLP2, and BLP3, respectively. In addition, 10 SPF chickens that were not immunized comprised the Unvaccinated group. Blood was collected from 5 members of each group weekly for 35 days. Levels of IgG antibodies in the sera were then assayed using ELISA. Weight gain and the feed conversion ratio of each group were also recorded weekly. Finally, 3 birds from each group were necropsied to evaluate probable lesions. The best results were obtained in the BLP1 group, with IBV vaccination at a low dose of admixed BLPs boosted immediate anti-IBV humoral responses; however, the results were not significantly different from those of the Control group, but were still feasible enough for application in the field. In conclusion, BLPs could be a desirable adjuvant for IBV vaccines to increase immunity in chickens.

Keywords:

Bacterium like particles IgG, adjuvant, infectious bronchitis, chicken,

___

1. Orr-Burks N, Gulley SL, Toro H, van Ginkel FW. Immunoglobulin A as an early humoral responder after mucosal avian coronavirus vaccination. Avian Diseases 2014; 58 (2): 279-286. doi: 10.1637/10740-120313-Reg.1
2. Jordan B. Vaccination against infectious bronchitis virus: a continuous challenge. Veterinary Microbiology 2017; 206: 137- 143. doi: 10.1016/j.vetmic.2017.01.002
3. Sjaak de Wit JJ, Cook JK, van der Heijden HM. Infectious bronchitis virus variants: A review of the history, current situation and control measures. Avian Pathology 2011; 40 (3): 323-335. doi: 10.1080/03079457.2011.566260
4. Jackwood MW, Jordan BJ, Roh HJ, Hilt DA, Williams SM. Evaluating protection against infectious bronchitis virus by clinical signs, ciliostasis, challenge virus detection, and histopathology. Avian Diseases 2015; 59 (3): 368-374. doi: 10.1637/11026-012415-reg.1
5. Bande F, Arshad SS, Bejo MH, Moeini H, Omar AR. Progress and challenges toward the development of vaccines against avian infectious bronchitis. Journal of Immunology Research 2015; 2015: 424860. doi: 10.1155/2015/424860
6. Cook JK, Jackwood M, Jones RC. The long view: 40 years of infectious bronchitis research. Avian Pathology 2012; 41 (3): 239-250. doi: 10.1080/03079457.2012.680432
7. Feng K, Xue Y, Wang J, Chen W, Chen F et al. Development and efficacy of a novel live-attenuated QX-like nephropathogenic infectious bronchitis virus vaccine in China. Vaccine 2015; 33 (9): 1113-1120. doi: 10.1016/j.vaccine.2015.01.036
8. Zhao Y, Cheng JL, Liu XY, Zhao J, Hu YX et al. Safety and efficacy of an attenuated Chinese QX-like infectious bronchitis virus strain as a candidate vaccine. Veterinary Microbiology 2015; 180: 49-58. doi: 10.1016/j.vetmic.2015.07.036
9. Yan S, Zhao J, Xie D, Huang X, Cheng J et al. Attenuation, safety, and efficacy of a QX-like infectious bronchitis virus serotype vaccine. Vaccine 2018; 36 (14): 1880-1886. doi: 10.1016/j.vaccine.2018.02.053
10. Li J, Helal ZH, Karch CP, Mishra N, Girshick T et al. A selfadjuvanted nanoparticle based vaccine against infectious bronchitis virus. PLoS One 2018; 13 (9): 1-17. doi: 10.1371/ journal.pone.0203771
11. Wang D, Lu J, Yu J, Hou H, Leenhouts K et al. A novel PspA protein vaccine intranasal delivered by bacterium-like particles provides broad protection against pneumococcal pneumonia in mice. Immunology Investigation 2018; 47 (4): 403-415. doi: 10.1080/08820139.2018.1439505
12. Lu J, Hou H, Wang D, Leenhouts K, Roosmalen MLV et al. Systemic and mucosal immune responses elicited by intranasal immunization with a pneumococcal bacteriumlike particle-based vaccine displaying pneumolysin mutant plym2. Immunology Letters 2017; 187: 41-46. doi: 10.1016/j. imlet.2017.05.003
13. Mao R, Wu D, Wang Y. Surface display on lactic acid bacteria without genetic modification: strategies and applications. Applied Microbiology and Biotechnology 2016; 100 (22): 9407-9421. doi: 10.1007/s00253-016-7842-8
14. Yu J, Li B, Chen X, Lu J, Wang D et al. Comparison of immunogenicity and protection of two pneumococcal protein vaccines based on PsaA and PspA. Infection and Immunology 2018; 86 (6): e00916-17. doi: 10.1128/IAI.00916-17
15. Bru T, Vila R, Cabana M, Geerligs HJ. Protection of chickens vaccinated with combinations of commercial live infectious bronchitis vaccines containing Massachusetts, Dutch and QX-like serotypes against challenge with virulent infectious bronchitis viruses 793B and IS/1494/06 Israel variant 2. Avian Pathology 2017; 46 (1): 52-58. doi: 10.1080/03079457.2016.1203393
16. Bosma T, Kanninga R, Neef J, Audouy SA, van Roosmalen ML et al. Novel surface display system for proteins on non-genetically modified gram-positive bacteria. Applied Environmental Microbiology. 2006; 72 (1): 880-889. doi: 10.1128/AEM.72.1.880- 889.2006
17. van Ginkel FW, Padgett J, Martinez-Romero G, Miller MS, Joiner KS et al. Age-dependent immune responses and immune protection after avian coronavirus vaccination. Vaccine 2015; 33 (23): 2655-2661. doi: 10.1016/j.vaccine.2015.04.026
18. Okino CH, Alessi AC, Montassier Mde F, Rosa AJ, Wang X et al. Humoral and cell-mediated immune responses to different doses of attenuated vaccine against avian infectious bronchitis virus. Viral Immunology 2013; 26 (4): 259-267. doi: 10.1089/ vim.2013.0015
19. Saluja V, Amorij JP, van Roosmalen ML, Leenhouts K, Huckriede A et al. Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant. The AAPS Journal 2010; 12 (2): 109-116. doi: 10.1208/s12248-009-9168-2
20. Sabroe I, Parker LC, Dower SK, Whyte MKB. The role of TLR activation in inflammation. Journal of Pathology 2008; 214 (2): 126-135. doi: 10.1002/path.2264
21. Smith KD. Toll-like receptors in kidney disease. Current Opinions in Nephrology and Hypertension 2009; 18 (3): 189- 196. doi: 10.1097/MNH.0b013e32832a1d5f
22. Okino CH, Mores MA, Trevisol IM, Coldebella A, Montassier HJ et al. Early immune responses and development of pathogenesis of avian infectious bronchitis viruses with different virulence profiles. PLoS One 2017; 12 (2): 1-17. doi: 10.1371/journal. pone.0172275
23. Lopes PD, Okino CH, Fernando FS, Pavani C, Casagrande VM et al. Inactivated infectious bronchitis virus vaccine encapsulated in chitosan nanoparticles induces mucosal immune responses and effective protection against challenge. Vaccine 2018; 36 (19): 2630-2636. doi: 10.1016/j.vaccine.2018.03.065
24. Tan L, Liao Y, Fan J, Zhang Y, Mao X et al. Prediction and identification of novel IBV S1 protein derived CTL epitopes in chicken. Vaccine 2016; 34 (3): 380-386. doi: 10.1016/j. vaccine.2015.11.042
25. de Wit JJS, Malo A, Cook JKA. Induction of IBV strain-specific neutralizing antibodies and broad spectrum protection in layer pullets primed with IBV Massachusetts (Mass) and 793B vaccines prior to injection of inactivated vaccine containing Mass antigen. Avian Pathology 2019; 48 (2): 135-147. doi: 10.1080/03079457.2018.1556778
26. de Wit JJ, Cook JK. Factors influencing the outcome of infectious bronchitis vaccination and challenge experiments. Avian Pathology 2014; 43 (6): 485-497. doi: 10.1080/03079457.2014.974504.
27. Smialek M, Tykalowski B, Dziewulska D, Stenzel T, Koncicki A. Immunological aspects of the efficiency of protectotype vaccination strategy against chicken infectious bronchitis. BMC Veterinary Research 2017; 13 (1): 1-7. doi: 10.1186/ s12917-017-0963-1
28. Leenhouts K. MimopathTM-based vaccine delivery. In: Singh M (editor). Novel immune potentiators and delivery technologies for next generation vaccines. Cambridge, MA, USA: Springer; 2013. pp. 245-265
29. Keijzer C, Haijema BJ, Meijerhof T, Voorn P, de Haan A et al. Inactivated influenza vaccine adjuvanted with bacteriumlike particles induce systemic and mucosal influenza. A virus specific T-Cell and B-Cell responses after nasal administration in a TLR2 dependent fashion. Vaccine 2014; 32 (24): 2904- 2910. doi: 10.1016/j.vaccine.2014.02.019
30. Shi W, Kou Y, Jiang H, Gao F, Kong W et al. Novel intranasal pertussis vaccine based on bacterium-like particles as a mucosal adjuvant. Immunology Letters 2018; 198: 26-32. doi: 10.1016/j.imlet.2018.03.012
31. de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML et al. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration. Vaccine 2012; 30 (32): 4884-4891. doi: 10.1016/j.vaccine.2012.04.032
32. Matoo JJ, Bashir K, Kumar A, Krishnaswamy N, Dey S et al. Resiquimod enhances mucosal and systemic immunity against avian infectious bronchitis virus vaccine in the chicken. Microbial Pathogenesis 2018; 119: 119-124. doi: 10.1016/j. micpath.2018.04.012
33. Ramirez K, Ditamo Y, Rodriguez L, Picking WL, van Roosmalen ML et al. Neonatal mucosal immunization with a non-living, non-genetically modified lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection. Mucosal Immunology 2010; 3 (2): 159-171. doi: 10.1038/mi.2009.131
34. Rigter A, Widjaja I, Versantvoort H, Coenjaerts FE, van Roosmalen M et al. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles. PLoS One 2013; 8 (8): e71072. doi: 10.1371/journal.pone.0071072
35. Heine SJ, Franco-Mahecha OL, Chen X, Choudhari S, Blackwelder WC et al. Shigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice. Immunology and Cell Biology 2015; 93 (7): 641-652. doi: 10.1038/icb.2015.24
36. Lu J, Guo J, Wang D, Yu J, Gu T et al. Broad protective immune responses elicited by bacterium-like particle-based intranasal pneumococcal particle vaccine displaying PspA2 and PspA4 fragments. Human Vaccine Immunotherapy 2019; 15 (2): 371- 380. doi: 10.1080/21645515.2018.1526556
37. de Wit JJ, Swart WA, Fabri TH. Efficacy of infectious bronchitis virus vaccinations in the field: Association between the α-IBV IgM response, protection and vaccine application parameters. Avian Pathology 2010; 39 (2): 123-131. 10.1080/03079451003604639